

September 1, 2026



# ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

## Conference details below:

### **September 9-11: Cantor Global Healthcare Conference**

Location: New York, NY

Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET

Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer

Webcast link: [Click Here](#)

### **September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference**

Location: New York, NY

Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1

Webcast link: [Click Here](#)

### **September 14-16: H.C. Wainwright 28<sup>th</sup> Annual Global Investment Conference**

Location: New York, NY

Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4<sup>th</sup> floor)

Webcast link: [Click Here](#)

### **September 21 (World Alzheimer's Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer's Day at the Nasdaq Tower**

Location: Nasdaq Tower, New York, NY

### **September 29: Roth Healthcare Opportunities Conference**

Location: New York, NY

During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company's EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company's lead candidate in the ongoing

PRECISE-AD Phase 1b trial in early Alzheimer's disease.

ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.

Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website. [Click Here](#)

### **About ProMIS Neurosciences Inc.**

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

### **Investor Relations Contact:**

Carie Pierce, VP, Investor Relations & External Affairs

IR@promisneurosciences.com



Source: ProMIS Neurosciences Inc.